Trial · NCT07887646
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1a : Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | Approximately 1 month | |
| Primary | Part 1a and Part 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs) | From first dose until 30 days after the last dose; approximately 13 months | |
| Secondary | Overall response rate (ORR) Assessed by Investigator | Approximately 24 months | ORR is defined as the percentage of participants with a best overall response of partial response or better per the Lugano Classification for non-Hodgkin lymphoma |
| Secondary | Complete response rate (CRR) | Approximately 24 months | CRR is defined as the percentage of participants with a best overall response of complete response per the Lugano Classification |
| Secondary | Duration of response (DOR) | Approximately 24 months | DOR is defined as the time from the first response to documented disease progression or death due to any cause, whichever occurs first |
| Secondary | Time to response (TTR) | Approximately 24 months | TTR is defined as the time from first dose to the first response |
| Secondary | Maximum Observed Plasma Concentration (Cmax) of BG-T0920 | Up to 1 month | |
| Secondary | Trough Concentration (Ctrough) of BG-T0920 | Up to 13 months | |
| Secondary | Area Under the Plasma Concentration-time Curve (AUC) of BG-T0920 | Up to 13 months | |
| Secondary | Serum concentration of BG-T0920 | Up to 13 months | |
| Secondary | Percentage of Participants Developing Antidrug Antibodies Against BG-T0920 | Up to 13 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07887646/registered